UV 2
Alternative Names: TENDU; UV-2; UV2 synthetic peptide vaccineLatest Information Update: 18 Jun 2024
At a glance
- Originator Ultimovacs AS
- Class Antineoplastics; Cancer vaccines; Immunotherapies; Peptide vaccines; Synthetic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Prostate cancer
Most Recent Events
- 05 Apr 2024 Pharmacodynamics and adverse events data from the phase I TENDU trial in Prostate cancer presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 04 Apr 2024 Phase I clinical development of UV 2 is still going on in Norway (NCT04701021)
- 28 Mar 2024 No recent reports of development identified for phase-I development in Prostate-cancer(In the elderly, Second-line therapy or greater, In adults) in Norway (SC, Injection)